By SmashMeals Editorial — 2026-10-01 — Health & Nutrition
The short answer
Retatrutide remains investigational and is not FDA-approved. In the peer-reviewed Phase 3 TRIUMPH-1 trial, 2,339 adults with obesity without diabetes were randomized to weekly retatrutide or placebo for 80 weeks. Mean weight change was −17.6%, −23.7% and −25.0% across the 4-, 9- and 12-mg groups versus −3.9% with placebo; gastrointestinal events were the most common adverse events.
Key facts
- The Phase 3 TRIUMPH-1 paper was published in the New England Journal of Medicine on Sept. 29, 2026.
- Retatrutide activates GIP, GLP-1 and glucagon receptors.
- The trial randomized 2,339 adults with obesity without diabetes.
- Mean weight change reached −25.0% in the 12-mg group versus −3.9% with placebo under the trial's treatment-regimen estimand.
- Retatrutide is still investigational and not available for public prescribing.
- FDA says retatrutide cannot be used in compounding under federal law.
KINGSPORT, Tenn., Oct. 1, 2026 — Retatrutide has moved from attention-grabbing topline numbers to peer-reviewed Phase 3 evidence. The New England Journal of Medicine published TRIUMPH-1 on Sept. 29, providing a detailed look at the investigational triple-receptor agonist in adults with obesity.
Retatrutide is not FDA-approved. SmashMeals does not sell, recommend or provide access to retatrutide. This article reports on research and food-related questions only.
What TRIUMPH-1 found
Researchers randomized 2,339 adults with obesity without diabetes to once-weekly retatrutide at 4 mg, 9 mg or 12 mg, or placebo, for 80 weeks. Mean body-weight change was −17.6%, −23.7% and −25.0% across the retatrutide groups versus −3.9% with placebo under the treatment-regimen estimand. Gastrointestinal events were the most common adverse events.
The study also included prespecified groups with knee osteoarthritis and obstructive sleep apnea and reported improvements in those outcomes. Trial averages do not predict one individual's response.
Why the nutrition question matters
Large weight changes and appetite-altering therapies raise a practical question: can a person continue meeting protein, micronutrient, fluid and energy needs while eating substantially less? Current GLP-1 nutrition guidance already emphasizes adequate protein, nutrient density, hydration and resistance exercise when appropriate. Retatrutide-specific nutrition protocols should not be invented before regulators and clinical guidance establish them.
Do not buy 'retatrutide' from the gray market
Lilly says retatrutide is available only through its clinical trials, and FDA says retatrutide cannot be used in compounding under federal law. A vial sold online with the drug's name on the label is not proof of identity, purity, dose or sterility.
What SmashMeals can legitimately help with
SmashMeals can make ordinary food logistics easier: fully prepared meals, visible nutrition information, flexible portions and a dedicated gluten-free kitchen. For approved GLP-1 therapies, use our GLP-1 nutrition hub. For the research pipeline, see our retatrutide research guide.
Commentary, not medical advice
The SmashMeals perspective
SmashMeals does not recommend or sell retatrutide. The food question is forward-looking: if next-generation obesity medicines produce very large reductions in body weight and appetite, clinicians and patients will need to pay close attention to adequate nutrition, protein, hydration, tolerability and preservation of strength. Those principles should be grounded in clinical guidance, not invented 'retatrutide diets.'
Frequently asked questions
Is retatrutide FDA-approved?
No. Retatrutide remains investigational as of October 1, 2026 and is being studied in Phase 3 trials.
Can a compounding pharmacy legally make retatrutide?
FDA states that retatrutide cannot be used in compounding under federal law. Products sold to consumers as compounded retatrutide should not be treated as an FDA-approved prescription alternative.
Is there an official retatrutide diet?
No. Retatrutide is investigational, and there is no FDA-approved retatrutide diet. Nutrition questions should be grounded in the trial evidence and established obesity-treatment nutrition guidance rather than invented protocols.
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity — New England Journal of Medicine
Why it matters: Primary peer-reviewed Phase 3 TRIUMPH-1 publication. - What to know about retatrutide — Eli Lilly and Company
Why it matters: Developer status page confirming retatrutide remains investigational and unavailable for public use. - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration
Why it matters: FDA states retatrutide cannot be used in compounding and is not a component of an FDA-approved drug.